Cel-Sci Corporation (NASDAQ:CVM)’s share price hit a new 52-week high on Friday . The stock traded as high as $14.99 and last traded at $14.33, with a volume of 4912 shares traded. The stock had previously closed at $14.12.

Several research analysts recently weighed in on CVM shares. BidaskClub upgraded Cel-Sci from a “hold” rating to a “buy” rating in a research report on Wednesday. HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of Cel-Sci in a research note on Monday, January 13th.

Cel-Sci (NASDAQ:CVM) last released its quarterly earnings results on Monday, December 16th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.11). The business had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.10 million.

Cel-Sci Company Profile (NASDAQ:CVM)

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of primary head and neck cancer. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer.

Further Reading: Certificate of Deposit (CD) For Risk Adverse Investors?

Receive News & Ratings for Cel-Sci Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cel-Sci and related companies with MarketBeat.com's FREE daily email newsletter.